Comp360 Competitors

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. We further our mission by: ● Developing psychedelics and marijuana into prescription medicines ● Training therapists and working to establish a network of treatment centers ● Supporting scientific research into spirituality, creativity, and neuroscience ● Educating the public honestly about the risks and benefits of psychedelics and marijuana

We’re on a mission to revolutionize mental healthcare

Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.